Diabetologia

, Volume 19, Issue 1, pp 1–9

Insulin aggregation in artificial delivery systems

  • W. D. Lougheed
  • H. Woulfe-Flanagan
  • J. R. Clement
  • A. M. Albisser
Review Articles

Conclusions

Abrupt changes in flow path, motion, elevated temperatures, metal ion contamination, impure insulin formulations, CO2 diffusion, pH drop, dissimilar metal pump components, salt concentration, inappropriate diluents, elevated temperatures, refrigeration temperatures, processing, insulin heterogeneity, and buffering systems have been implicated to a greater or lesser extent in the plugging of insulin delivery devices. Before the rate at which insulin loses its biological activity in delivery systems can be assessed it is obvious that anti-aggregating diluents must be developed and subjected to long-term testing both in vitro and in vivo. Until such stable homogenous formulations are available the knowledge presented in this article will serve to decrease, but not eliminate, the problem of insulin aggregation in delivery systems. Further experiments are in progress and preliminary results [41] provide evidence that the problems cited are not without resolution. In this regard serum apparently contains factor(s) that promote the dissolution of insulin and prevent the formation of peptide aggregates in dilute solutions [41]. Many laboratories are now working to resolve the problem of insulin aggregation in artificial delivery devices.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jackman WS, Lougheed W, Marliss EB, Zinman B, Albisser AM (1980) For insulin infusion: A miniature precision peristaltic pump and silicone rubber reservoir. Diabetes Care 3: 322–331Google Scholar
  2. 2.
    Goriya Y, Bahoric A, Marliss EB, Zinman B, Albisser AM (1979) Glycaemic regulation using a preprogrammed insulin delivery device. III. Long-term studies on diabetic dogs. Diabetes 28: 558–564Google Scholar
  3. 3.
    Irsigler K, Kritz H (1979) Long term continuous intravenous insulin therapy with a portable insulin dosage-regulating apparatus. Diabetes 28: 196–203Google Scholar
  4. 4.
    Jeffrey PD, Milthorpe BK, Nichol LW (1976) Polymerization pattern of insulin at pH 7.0. Biochemistry 15: 4660–4665Google Scholar
  5. 5.
    Jeffrey PD (1974) Polymerization behaviour of bovine zincinsulin at neutral pH. Molecular weight of the subunit and the effect of glucose. Biochemistry 13: 4441–4447Google Scholar
  6. 6.
    Pickup JC, Keen H, Parsons JA, Alberti KGMM (1978) Continuous subcutaneous insulin infusion: An approach to achieving normoglycemia. Br Med J 1: 204–207Google Scholar
  7. 7.
    Pickup JC, White MC, Keen H, Parsons JA, Alberti KGMM (1979) Long-term continuous subcutaneous insulin infusion in diabetics at home. Lancet II: 870–874Google Scholar
  8. 8.
    Blundell TL, Dodson GG, Dodson EJ, Hodgkin DC, Vijayan M (1971) X-ray analysis and the structure of insulin. Recent Prog Horm Res 27: 140Google Scholar
  9. 9.
    Cunningham LW, Fisher RL, Vestling CS (1955) A study of the binding of zinc and cobalt by insulin. J Am Chem Soc 77: 5703–5707Google Scholar
  10. 10.
    Fredericq E (1954) La cour de la titration de l'insulin et de ses tractions. J Polymer Sci 12: 287–300Google Scholar
  11. 11.
    Gutfreund H (1952) Reversible disassociation of insulin and its molecular weight. Biochem J 50: 564–569Google Scholar
  12. 12.
    Goldman J (1971) Ph. D. thesis, Univ. of Calif., BerkeleyGoogle Scholar
  13. 13.
    Grant PT, Coombs TL, Frank BH (1972) Differences in the nature of the interaction of insulin and proinsulin with zinc. Biochem J 126: 433–440Google Scholar
  14. 14.
    Hodgkin DC (1974) Varieties of insulin. Proc Soc Endocrinol 3P–13PGoogle Scholar
  15. 15.
    Laskowski MJr, Widom JM, McFadden ML, Scheraga HA (1956) Differential ultraviolet spectra of insulin. Biochim Biophys Acta 19: 581–582Google Scholar
  16. 16.
    Oncley JL, Ellenbogen E, Gitlen D, Gurd FRN (1952) Protein interactions. J Physiol Chem 56: 85–92Google Scholar
  17. 17.
    Paselk RA, Levy D (1974) Fluorine nuclear magnetic resonance studies of triflouracetyl-insulin derivatives. Effects of pH on conformation and aggregation. Biochemistry 13: 3340–3345Google Scholar
  18. 18.
    Pekar AH, Frank BH (1972) Conformation of proinsulin. A comparison of insulin and proinsulin self-association at neutral pH. Biochemistry 11: 4013–4016Google Scholar
  19. 19.
    Praissman M, Rupley JA (1968) Comparison of protein structure in the crystal and in solution. II. Tritium-hydrogen exchange of zinc-free and zinc insulin. J Biochem 7: 2431–2445Google Scholar
  20. 20.
    Steiner RM (1952) Reversible association processes of globular proteins. I. Insulin. Arch Biochem Biophys 39: 333–354Google Scholar
  21. 21.
    Waugh D (1954) Protein-protein interactions. Adv Protein Chem 9: 325–437Google Scholar
  22. 22.
    Holladay LA, Ascoli M, Puett D (1977) Conformational stability and self-association of zinc-free bovine insulin at neutral pH. Biochim Biophys Acta 494: 245–254Google Scholar
  23. 23.
    Thurow H (1979) Studies on the denaturation of dissolved insulin. 2nd International Insulin Symposium, AachenGoogle Scholar
  24. 24.
    Wu Gay-May (1974) Purification, stability and physico-chemical behaviour of bovine insulin. Dissertation Abstracts Vol. 35, no. 75-7816Google Scholar
  25. 25.
    Jackson PL, Storvick CS, Hollinden CS, Stroeth L, Still ZJG (1971) Neutral regular insulin (Abstracts). Diabetes 20 (Suppl 1): 361Google Scholar
  26. 26.
    Mirsky IA, Kawamura K (1966) Heterogeneity of crystalline insulin. Endocrinology 78: 1115–1119Google Scholar
  27. 27.
    Steiner DF, Terris S, Chan SJ, Rubenstein AH (1976) Chemical and biological aspects of insulin and proinsulin. pp. 53–92. In: Luft R (ed) Insulin. A. Lindgren, Molndal, SwedenGoogle Scholar
  28. 28.
    Dillon WW, Romans RG (1967) Heterogeneity of insulin. II. Chromotography of insulin on carboxymethyl cellulose in urea containing buffers. Can J Biochem 45: 221–237Google Scholar
  29. 29.
    Schlichtkrull J (1979) Insulin in perspective. IDF Bull 24: 7–10Google Scholar
  30. 30.
    Yue DK, Turtle JY (1975) Antigenicity of “Monocomponent” pork insulin in diabetic subjects. Diabetes 24: 625–632Google Scholar
  31. 31.
    Schlichtkrull J (1977) Purity and antigenicity of insulin preparations. Acta Paediatr Scand [Suppl] 270: 37–40Google Scholar
  32. 32.
    Mahbouba M, Smith HJ (1977) Thiolation and disulphide cross-linking of insulin to form macromolecules of potential therapeutic value. Adv Exp Med Biol 86A: 247–259Google Scholar
  33. 33.
    Massey DE, Smyth DG (1972) The effect of acylation on the molecular size of insulin. Eur J Biochem 31: 470–473Google Scholar
  34. 34.
    Maloney PJ, Aprile MA, Wilson S (1964) Sulphated insulin for treatment of insulin resistant diabetics. J New Drugs 4: 258–263Google Scholar
  35. 35.
    Stephenson NR, Romans RG (1960) Thermal stability of insulin made from zinc insulin crystals. J Pharm Pharmacol XII: 372–376Google Scholar
  36. 36.
    Pingel M, Vølund A (1972) Stability of insulin preparations. Diabetes 21: 805–813Google Scholar
  37. 37.
    Nolan C, Margoliash E, Peterson JD, Steiner DF (1971) The structure of bovine insulin. J Biol Chem 246: 2780–2787Google Scholar
  38. 38.
    Thurow H (1979) The stability of highly concentrated neutral insulin solutions. IDF Abstr.; Workshop on artificial beta cell in diabetes research and management. Proceedings, p 13Google Scholar
  39. 39.
    Lougheed W, Albisser AM (1980) Insulin delivery and the artificial beta cell: Luminal obstructions in capillary conduits. Int J Artificial Org 3: 50–56Google Scholar
  40. 40.
    Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685Google Scholar
  41. 41.
    Albisser AM, Lougheed W, Perlman K, Bahoric A (1980) Non-aggregating insulin solutions for long-term glucose control in experimental and human diabetes. Diabetes 29: 241–243Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • W. D. Lougheed
    • 1
  • H. Woulfe-Flanagan
    • 2
  • J. R. Clement
    • 2
  • A. M. Albisser
    • 1
    • 3
  1. 1.The Hospital for Sick ChildrenTorontoCanada
  2. 2.Connaught Laboratories LimitedTorontoCanada
  3. 3.Biomedical ResearchThe Hospital for Sick ChildrenTorontoCanada

Personalised recommendations